Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists by Hamel, Lauren M et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Hematology Oncology Articles Hematology-Oncology 
3-1-2017 
Do Patients and Oncologists Discuss the Cost of Cancer 
Treatment? An Observational Study of Clinical Interactions 
Between African American Patients and Their Oncologists. 
Lauren M. Hamel 
Louis A. Penner 
Susan Eggly 
Robert Chapman 
Henry Ford Health System 
Justin F. Klamerus 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/
hematologyoncology_articles 
Recommended Citation 
Hamel LM, Penner LA, Eggly S, Chapman R, Klamerus JF, Simon MS, Stanton SC, Albrecht TL. Do Patients 
and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions 
Between African American Patients and Their Oncologists. J Oncol Pract. 2017 Mar;13(3):e249-e258. 
This Article is brought to you for free and open access by the Hematology-Oncology at Henry Ford Health System 
Scholarly Commons. It has been accepted for inclusion in Hematology Oncology Articles by an authorized 
administrator of Henry Ford Health System Scholarly Commons. 
Authors 
Lauren M. Hamel, Louis A. Penner, Susan Eggly, Robert Chapman, Justin F. Klamerus, Michael S. Simon, 
Sarah CE Stanton, and Terrance L. Albrecht 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
hematologyoncology_articles/85 
Karmanos Cancer Institute, Wayne State
University and Josephine Ford Cancer
Institute, Henry Ford Health System,
Detroit, MI
Corresponding author: Lauren M. Hamel,
PhD, Karmanos Cancer Institute, Wayne
State University, 4100 John R. St,
Mailcode MM03CB, Detroit, MI 48201;
e-mail: hamell@karmanos.org.
Disclosures provided by the authors are
available with this article at
jop.ascopubs.org.
DOI: 10.1200/JOP.2016.015859;
published online ahead of print at
jop.ascopubs.org on December 13,
2016.
Do Patients and Oncologists Discuss the Cost of Cancer
Treatment? An Observational Study of Clinical
Interactions Between African American Patients and
Their Oncologists
Lauren M. Hamel, Louis A. Penner, Susan Eggly, Robert Chapman, Justin F. Klamerus, Michael S. Simon, Sarah C.E.
Stanton, and Terrance L. Albrecht
QUESTION ASKED: Do African American
patients with cancer and medical oncologists
discuss cancer treatment costs, and if so, who
initiates the discussion andwhat cost topics are
discussed?
SUMMARY ANSWER: Treatment cost dis-
cussions occurred in 45% of clinical in-
teractions between African American patients
with cancer and their medical oncologists.
Patients initiated 63% of discussions; oncol-
ogists initiated 36%. (One discussion was
initiated by a patient’s companion.) Themost
frequent topics were concern about time off
from work for treatment (initiated by pa-
tients) and insurance (initiated by oncologists).
Younger patients and patients with more
perceived social support satisfactionweremore
likely to discuss cost. Patient age interacted
with amount of social support to affect fre-
quency of cost discussions. Younger patients
with more social support had more cost dis-
cussions; older patients with more social
support had fewer cost discussions.
WHAT WE DID: A total of 103 African
American patients with cancer and 18 non–
African American medical oncologists met for
the first time to discuss treatment of breast,
lung, and colorectal cancer, and we video-
recorded that interaction. Patients and on-
cologists provided information on their soci-
odemographic characteristics and patients’
perceived amount of social support and sat-
isfaction with that social support. Trained
coders observed the video recordings for
the presence and duration of treatment cost
discussions. The coders then determined the
initiator, topic, oncologist response to the
patient’s concerns, and the patient’s reaction to
the oncologist’s response.
WHAT WE FOUND: Our findings of who
initiates cost discussions and what cost topics
are discussed in treatment discussions with
African American patients with cancer and
their medical oncologists may provide ad-
ditional understanding of what cost issues
are important to this underserved patient
population. Importantly,most cost discussions
focused on the impact of the diagnosis on
patients’ opportunity costs rather than on
direct treatment costs. This finding has an
important implication for ASCO’s Value
Framework, which does not include these
kinds of cost considerations and focuses ex-
clusively on direct treatment costs.
BIAS, CONFOUNDING FACTOR(S), REAL-
LIFE IMPLICATIONS: All the patients were
African American and more than 90% were
female, which may limit the generalizability of
the findings. This was a secondary analysis of a
larger study that was not focused on patient-
oncologist cost discussions. Thus, we were not
able to ask patients what they wanted to know
about treatment cost before the interaction or
assess patient level of understanding of cost
discussions after the interaction. The study
has important implications for how oncol-
ogists discuss cost with economically dis-
advantaged minority patients and professional
guidelines for cost discussions with patients
with cancer.
ReCAPs (Research
Contributions Abbreviated for
Print) provide a structured,
one-page summary of each
paper highlighting the main
findings and significance of
the work. The full version of
the article is available online at
jop.ascopubs.org.
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Discuss the Cost of Cancer
Treatment? AnObservational Study
of Clinical Interactions Between
African American Patients and
Their Oncologists
Lauren M. Hamel, PhD, Louis A. Penner, PhD, Susan Eggly, PhD, Robert Chapman, MD,
Justin F. Klamerus, MD, MMM, Michael S. Simon, MD, MPH, Sarah C.E. Stanton, PhD,
and Terrance L. Albrecht, PhD
Abstract
Purpose
Financial toxicity negatively affects patients with cancer, especially racial/ethnic minorities.
Patient-oncologist discussions about treatment-related costsmay reduce financial toxicity by
factoring costs into treatment decisions. This study investigated the frequency and nature of
costdiscussionsduringclinical interactionsbetweenAfricanAmericanpatientsandoncologists
and examined whether cost discussions were affected by patient sociodemographic
characteristics and social support, a known buffer to perceived financial stress.
Methods
Video recorded patient-oncologist clinical interactions (n = 103) from outpatient clinics of
two urban cancer hospitals (including a National Cancer Institute–designated
comprehensive cancer center) were analyzed. Coders studied the videos for the presence
and duration of cost discussions and then determined the initiator, topic, oncologist
response to the patient’s concerns, and the patient’s reaction to the oncologist’s response.
Results
Cost discussions occurred in 45% of clinical interactions. Patients initiated 63% of
discussions; oncologists initiated36%.Themost frequent topicswereconcernabout timeoff
from work for treatment (initiated by patients) and insurance (initiated by oncologists).
Younger patients and patients with more perceived social support satisfaction were more
likely todiscusscost.Patientageinteractedwithamountofsocial supporttoaffect frequency
of cost discussionswithin interactions. Younger patients withmore social support hadmore
cost discussions; older patients with more social support had fewer cost discussions.
Conclusion
Cost discussions occurred in fewer than one half of the interactions and most commonly
focused on the impact of the diagnosis on patients’ opportunity costs rather than
treatment costs. Implications for ASCO’s Value Framework and design of interventions to
improve cost discussions are discussed.
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INTRODUCTION
Financial toxicity, the increased financial burden from cancer
treatment and its influence on patient well-being, treatment
decisions, and health outcomes, negatively affects many pa-
tients with cancer.1-5 As the cost of cancer care escalates6 and
the burden of cost shifts to the patient,7-10 more patients are
incurring debt,11 filing for bankruptcy,12 deviating from cancer
treatment plans,1 and forgoing treatment.13 Recent evidence
also suggests that severe financial distress as a result of cancer
treatment may itself be a mortality risk factor.14
The encouragement of patients and physicians to discuss
treatment costs may help to alleviate financial toxicity and
facilitate more-informed treatment decisions.5,15-20 Such dis-
cussions are an opportunity for patients to voice cost con-
cerns and for physicians to provide information about costs
(if available) and to allow cost to factor into treatment
decisions.2,5,15,17 In fact, clinicians increasingly have been
encouraged to discuss treatment costs with patients as
economic concerns grow.5,17,21
The data on patient-physician treatment cost discussions
are inconsistent. Some studies show that patients want to
discuss treatment costs with their physicians,22 and most
physicians report that they frequently discuss cost with their
patients.23 However, other research has found that physicians
often are hesitant about initiating cost discussions24-26 and
rarely fully engage with patients to resolve their financial
concerns.27 Several studies suggest that discussions of treat-
ment costs in patient-physician clinical interactions are
rare.15,24-26,28,29
Given the potential importance of cost-related discussions
in cancer care, this study systematically assessed the extent and
natureofactual costdiscussions thatoccurbetweenasampleof
African American patients and their oncologists. This study
focused on African Americans because, on average, African
Americans are more likely than whites to have low annual
household incomes30 and, thus, may be at greater risk to incur
economic hardship as a result of a cancer diagnosis.31-35 In
addition, most African American patients with cancer ex-
perience racially discordant clinical interactions (ie, non–
African American physician with African American pa-
tient),36 and a significant body of research has found that
relative to racially concordant interactions, patient-physician
communication in racially discordant interactions is of poorer
quality.37-43
A secondary purpose of this study was to explore how
certain patient characteristics affect cost discussions. Research
has found that financial toxicity is an emotional stressor.3,4
Thus, patient perceptions of social support were examined
because social support has been found to be a buffer to fi-
nancial stress.44,45 Patients reported the amount of social
support they received and their satisfaction with that social
support. These aspects of social support are distinct and often
have a variety of effects on how people react to environ-
mental stressors.46,47 Given the likely association of patient
age, education, and annual household income with patient
finances, the influence of these sociodemographic character-
istics on cost discussions was also examined. To answer the
questions of interest in this study, real-time video-recorded
patient-oncologist clinical interactions were analyzed for fre-
quency and content of cost discussions.
METHODS
Participants and Setting
Data were from a larger parent study that tested a commu-
nication intervention in the outpatient clinics of two urban
cancer hospitals.48-50 The two hospitals provide the largest
proportion of cancer care for the residents of Detroit,
Michigan, a city with a majority African American pop-
ulation. Data were collected between March 2012 and De-
cember 2014. The current study was a secondary analysis
conducted after the parent study was completed.
Participants were African American patients with cancer
and their non–African American medical oncologists. The
oncologists and patients were meeting for the first time to
discuss treatment options for breast, lung, or colorectal cancer.
One clinical interaction for each patient was video recorded.
The parent study focused on patient-oncologist communi-
cation; thus, patients and physicians did not know that cost
discussions would subsequently be assessed.
Procedure and Measures
Upon recruitment into the parent study, patients and on-
cologists completed a baseline questionnaire that assessed
demographic characteristics and other personal attributes.
Patients provided information on their sociodemographic
characteristics and perceived social support.46 Patients were
presented with five social support domains, including de-
pendability (eg, Whom can you really count on to be de-
pendable when you need help?), help with relaxing,
unconditional acceptance, unconditional care, and consola-
tion. Patients reported the number of persons who provided
e250 Volume 13 / Issue 3 / March 2017 n Journal of Oncology Practice Copyright © 2016 by American Society of Clinical Oncology
Hamel et al
Downloaded from ascopubs.org by Henry Ford Hospital on December 18, 2019 from 150.198.017.009
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
them with social support in each domain and their level of
satisfaction with the support received (1 = very dissatisfied to
4 = very satisfied). Responses were summed across items for
each typeof support and then averaged across the five domains
to yield two scores for eachpatient.Higher scores indicatemore
perceived social support and greater satisfaction. Oncologists
provided information on their sex, race/ethnicity, age, and
number of years in practice since their fellowship.
Aspartof the larger study,patientswere randomlyassigned
to three study arms: control group (usual care); those who
received a question prompt list that contained questions pa-
tients might ask their oncologist; and those who received the
question prompt list and met with a coach who reviewed the
questionswith them.Approximately 1week later, patients and
their oncologist met to discuss treatment options.48 Patients
from all arms were included in this study, and each study arm
was controlled for in all analyses.
Each examination room was equipped with unobtrusive
digital audio and video devices that recorded all occupants of
the examination room during the clinical interaction. This
recording system has been used by the study team for more
than 15 years,51,52 and research has strongly suggested that
video recording has little impact on participants’ verbal or
nonverbal behaviors53 and provides enhanced validity com-
pared with audio recording alone.54
The study was approved by the institutional review boards
of the affiliated university and both hospitals. All patients,
companions (if present), and oncologists provided consent as
participants, which included specific permission to be video
recorded.
Oncologist and Patient Interaction Coding
Thefirstandseniorauthorswatched10video-recordedclinical
interactions from the data for examples of cost discussions to
develop a coding system that identified and described cost
discussions. Cost discussions were defined broadly24 as verbal
expressions of any perceivedmonetary expense for the patient
for cancer treatment. Topic categories for cost included out-
of-pocket expenses for treatment, insurance coverage, trans-
portation and parking for treatment, time off from work for
treatment and recovery, and loss of employment.
Two trained research assistant coders then observed all the
video-recorded interactions, (including those used to develop
the coding system). The coders assessed the frequency and
duration of cost discussions according to the aforementioned
topiccategories for costbyusingobservational codingsoftware
(Studiocode [www.studiocodegroup.com]; Vosaic, Lincoln,
NE). Cost discussions weremarked as beginning with the first
mention of cost and ending with the first mention of either a
noncost topic or a new cost topic. Both individual cost dis-
cussions and total clinical interaction time (total time the
oncologist and patient were in the examination room to-
gether) were assessed to the nearest second. For each cost
discussion, coders identified the initiator, topic, oncologist’s
response to the patient’s concern, and how the patient reacted
to the oncologist’s response.
Interrater reliability was assessed in two stages. First, the
coders were trained to assess the presence and duration of
the cost discussion; reliability was assessed by percentage of
agreement (presence, 88.3%; duration, 83.8%). Second, the
coders were trained to label discussion elements (initiator,
topic, oncologist response, and patient reaction). Reliability
was determined byCohenk (k = 0.84; an average kwas taken
across the coded elements). Because the high k value sug-
gested high intercoder reliability, each coder independently
coded approximately 40% of the interactions. The remaining
interactions were coded by both coders to assess continued
intercoder reliability, which remained high.
Data Analysis
Data included the video-recorded clinical interactions, patient
and oncologist self-reported sociodemographics, and patient-
reported amount of social support and social support satis-
faction. Bivariate associations between the outcome variables
andpatient age, education, income,perceivedamountof social
support and satisfaction with social support, and interaction
length were examined to identify possible predictors and
covariates to be included in the regression analyses.
The primary analyses of the predictors for the outcome
variables used generalized estimating equation (GEE)55,56 mul-
tiple regressions with robust standard error estimates to account
for patients being clustered within oncologist. Patient at-
tributes and other variables that correlated with the outcome
variables were included in the GEEs.
The first GEEused absence or presence of a cost discussion
as the outcome variable. For the clinical interactions that
included cost discussions, two more GEEs were conducted,
with frequency of cost discussions and total time spent in
discussion about cost as the outcome variables. Study arm to
which patients were assigned in the parent study was included
as a covariate in all regression analyses. For all analyses,a was
set at P , .05 (two-tailed).
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RESULTS
Of the 273 patients invited to participate in the parent study,
137 (50%) accepted. Patients who declined to participate did
so because of limited time or feeling burdened by their cancer.
An analysis of zip codes of participants and nonparticipants
suggested that they came from areas with similar socio-
demographic characteristics.50 Twenty-three patients were
excluded from this analysis because they were not video
recorded as a result of issues with equipment availability.
Eleven patients were excluded from this analysis because their
diagnosis did not warrant a discussion of medical treatment
(eg, ductal carcinoma in situ). Thus, the final sample was
composed of 103 patients.
The sociodemographic characteristics of the 103 African
American patients and their non–African American medical
oncologists (n = 18) are listed in Table 1. All patients self-
identified as African American, and most had breast cancer
(87%). Most patients (73%) reported annual household
Table 1. Patient and Oncologist Demographics
Demographic Total Cost Discussion No Cost Discussion
Patients*
No. of participants 103 46 57
Mean age, years (SD) 58.74 (10.82) 55.24 (10.30) 61.56 (10.47)
Female 95 (92) 41 (89) 54 (95)
Education
, High school 23 (22) 8 (17) 15 (26)
Graduated high school 12 (12) 5 (11) 7 (12)
Some college 34 (33) 18 (39) 16 (28)
Graduated college 21 (20) 8 (17) 13 (23)
Postgraduate degree 13 (13) 7 (15) 6 (11)
Marital status
Married or partnered 33 (32) 19 (41) 14 (25)
Divorced, widowed, or separated 38 (37) 16 (35) 22 (39)
Single 30 (29) 10 (22) 20 (35)
Annual household income
$0-$19,999 43 (42) 17 (37) 26 (46)
$20,000-$39,999 31 (30) 15 (33) 16 (28)
$40,000-$59,999 8 (8) 4 (9) 4 (7)
$60,000-$79,999 8 (8) 3 (7) 5 (9)
. $80,000 7 (7) 4 (9) 3 (5)
Primary tumor site
Breast 89 (86) 38 (83) 51 (90)
Colorectal 7 (7) 4 (9) 3 (5)
Lung 7 (7) 4 (9) 3 (5)
Mean interaction time, minutes (SD) 31.01 (14.14) 34.57 (13.84) 28.08 (13.82)
Amount of social support score, mean (SD) 4.03 (2.36) 4.67 (2.36) 3.52 (2.24)
Social support satisfaction score, mean (SD) 3.71 (0.61) 3.84 (0.33) 3.59 (0.75)
Oncologists
No. of participants 18
Mean age, years (SD) 46.76 (10.60)
Male 10 (56)
Race/ethnicity
White 10 (56)
Asian or Pacific Islander 4 (22)
Arab American or Middle Eastern 4 (22)
Attending 15 (83)
Years in practice since fellowship, mean (SD) 7.69 (9.83)
NOTE. Values are No. (%) unless otherwise indicated.
Abbreviation: SD, standard deviation.
*Some data are missing because of omissions in patients’ responses.
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incomes of , $40,000. Ten of the 18 oncologists were male,
56% reported their race as white, 22% reported being Asian or
Pacific Islander, and 22% reported being Arab American or
Middle Eastern. On average, each oncologist saw six patients
(range, 1 to 25 patients).
Occurrence and Nature of Cost Discussions
Cost discussions occurred in 46 (45%) of 103 patient-
oncologist clinical interactions. One to six cost discus-
sions occurred per interaction for a total of 88 (mean, 1.91;
standard deviation [SD], 1.46). Individual cost discussions
lastedanaverageof 35.72 seconds (SD, 34.85 seconds).Total
average time spent in discussion about cost within the entire
clinical interaction was 1.14 minutes (SD, 1.18 minutes),
which comprised an average of 3.28% (SD, 0.03%) of the
interaction length. Twenty-nine patients initiated 55 (63%)
of the 88 cost discussions; 11 oncologists initiated 32 (36%)
discussions. Companions were present in 59% of in-
teractions, and one companion (1%) initiated one cost
discussion (Table 2).
Patient-initiated discussions
In the 55 patient-initiated cost discussions, concern about
having to take time off from work for treatment or recovery
was the most frequent topic (56%) followed by insurance
questions or concerns (16%); transportation and parking
costs (11%); concerns about loss of employment as a result
of extended time off from work for treatment and recovery
(7%); out-of-pocket costs for treatment, such as copayments
(6%); and general financial concerns (4%). Oncologists’ re-
sponses to patient-initiated discussions were to address the issue
directly (69%); to refer thepatient toanotherhealthcareprovider,
such as a social worker (20%); or to not address the issue (11%).
Most patients (78%) were observed to agree or be satisfied
with the oncologist’s response to patient-initiated discussions
(most frequently with a head nod or by saying okay or yes).
Patients demonstrated disagreement or dissatisfaction in 6%
of discussions (usually observed as a head shake or similar
nonverbal behavior). The patient changed the topic in 7% of
the discussions, and the oncologist changed topic in 9%. The
switch to a cost topic occurred twice.
Table 2. Cost Discussions by Initiator and Topic Within Clinical Interactions
Cost Discussion Clinical Interaction, %
Initiator and Topic First Second Third Fourth Fifth Sixth Total, No.
Patient
No. of participants 22 14 9 3 4 3 55
Time off from work 68 71 33 33 25 33
Transportation/
parking
18 7
Insurance 14 7 11 67 25 33
Treatment costs 7 11 33
Job loss 7 33 25
General concern 11 25
Oncologist
No. of participants 24 5 1 1 0 1 32
Time off work 38 60
Transportation/
parking
8 20
Insurance 42 20 100 100
Treatment costs 8 100
General concern 4
Companion
No. of participants 0 1 0 0 0 0 1
Insurance 100
Total, no. of
participants
46 20 10 4 4 4 88
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Oncologist-initiated discussions
In the 32 oncologist-initiated cost discussions, insurance was
the most frequent topic (41%) followed by time off fromwork
(38%), transportation and parking costs (9%), out-of-pocket
costs for treatment (9%), and general financial concerns (3%).
If an oncologist initiated a discussion, he or she always
addressed the topic.
Coders judged the majority of patients (66%) to be either
in agreement or satisfied with the oncologist’s response to
oncologist-initiated discussions. Patients always provided
answers to oncologist-posed questions in the remaining 34%
of oncologist-initiated discussions.
Correlates of Cost Discussions
Bivariate associations between the outcome variables (ie,
presence of a cost discussion, frequency of a cost discussion
within a single clinical interaction, time spent in discussion
aboutcost) andpatient age, income, education, and interaction
length identified patient demographic characteristics (ie, age,
income, education) to be included in the GEE analyses of
thecostdiscussions.Theonlycharacteristicassociatedwith the
outcome variables was patient age, which was significantly
(P# .05) and negatively correlated with presence of a cost dis-
cussion (r =20.29), frequency of cost discussions (r =20.26),
and time spent in discussion about cost (r = 20.22).
Perceived amount of social support was significantly and
positively correlated with the presence of a cost discussion
(r = 0.24), frequency of cost discussions (r = 0.29), and time
spent in discussion about cost (r = 0.26). Perceived satis-
faction with social support was significantly and positively
associated with presence of a cost discussion (r = 0.21) and
time spent in discussion about cost (r = 0.26).
As would be expected, interaction length was significantly
and positively correlatedwith the presence of a cost discussion
(r = 0.23), frequency of cost discussions (r = 0.33), and time
spent in discussion about cost (r = 0.35).
Thus, the following were included as predictors in the GEE
analyses: patient age, amount of social support, and satisfaction
with social support. Interaction length was included as a co-
variate. Although the outcome variables did not significantly
differ by study arm, study arm was also included in the models
asacovariatebecauseother research50 has found that the parent
study intervention affected the level of patient participation.
TheGEE analysis of the predictors of the presence of a cost
discussion revealed that patient age was negatively associated
with the probability that cost was discussed (B = 20.15;
standard error [SE], 0.07; P = .05; odds ratio [OR], 4.0; 95%
CI, 20.3 to 20.003), and perceived satisfaction with social
supportwas positively associatedwith the probability that cost
was discussed (B = 0.08; SE, 0.03; P = .009; OR, 6.9; 95% CI,
0.02 to 0.15). The perceived amount of social support was not
associated with the probability that cost was discussed. There
were no significant interactions.
For clinical interactions that included a cost discussion, the
GEEanalysiswith frequencyofcostdiscussionsas theoutcome
variable found no significant bivariate associations with age or
the two aspects of social support. However, a significant in-
teractionwas foundbetweenpatientageandperceivedamount
of social support that affected the frequency of cost discussions
(B = 20.55; SE, 0.11; P , .001; OR, 26.8; 95% CI, 20.76
to 20.34; Fig 1). Among younger patients (21 SD), a sig-
nificant positive association was found between perceived
amount of social support and frequency of cost discussions (ie,
more perceived support, higher frequency of discussions).
However, among older patients (+1 SD), a significant negative
association was found between perceived amount of social
support and frequency of cost discussions (ie, more perceived
support, lower frequency of discussions).
The GEE analysis of the predictors of time spent in dis-
cussion about cost revealed neither age nor either aspect of
social support to be significantly associated.
DISCUSSION
To our knowledge, this study is the first to use video-recorded
patient-oncologist clinical interactions to identify and code
treatment cost discussions. Thediscussionof cancer treatment
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costs with patients is purported to be a key component of
high-quality care18 andmay alleviate financial toxicity.5,15-20
Most physicians report that they discuss cost with patients,23
but a cost discussion occurred in fewer than one half of the
clinical interactions observed in this study. Most cost dis-
cussions were patient initiated and focused on indirect or
opportunity costs of cancer care rather than on the direct
costs of treatment. Thus, the treatment-related cost topics
that patients discussed were not those considered in the
common definition of treatment costs used by the aca-
demic and medical communities.1,5,17,21
The Influence of Age and Social Support on Cost
Discussions
The reason for the negative association between age and cost
discussions is not immediately clear but may involve em-
ployment and insurance. The most frequent patient-initiated
cost topic was time off from work. Older patients were more
likely to be retired and less likely to raise the issue of work in
treatment discussions. Furthermore, in the United States, a
person is eligible for Medicare at the age of 65 years. Perhaps
cost was discussed less in clinical interactions with older pa-
tientsbecauseof anassumptionby thepatientor theoncologist
that Medicare would cover treatment costs.
Patient-perceived social environment also influenced cost
discussions with oncologists. Supportive relationships appear
to matter to patients who have limited financial resources and
influence their mind-sets when they face the realities of
cancer treatment. The majority of patients (73%) reported
an annual household income of less than $40,000; hence,
social environment may have created a basis for the salience
of treatment-related costs. Perhaps patients weremore likely
to discuss costs because their family and friends urged them
to do so. More research would help to clarify this situation.
For older patients, less perceived amount of social support
was associated with more cost discussions, whereas more
perceived amount of social support was associated with fewer
cost discussions. Perhaps for older patients, a lack of satis-
faction with social support prompted them to look to their
physician for support with cost issues. Further research will
help to elucidate this finding.
Implications for ASCO’s Value of Cancer Treatment
Options Framework
The topics of discussions observed in this study should be
considered in the context of the ASCO Value of Cancer
Treatment Options Framework.17,18,21 ASCO’s Value Frame-
work weighs clinical benefit and toxicity against cost of treat-
ment and prompts oncologist-patient discussions of treatment
value.However, thedefinitionof cost in the framework is limited
to a patient’s direct expenses (eg, copayments).57 Thus many of
the cost issues observed in this study would not be taken into
account within the framework. This is a particular concern for
minority patients who are especially vulnerable to financial
toxicity caused by direct11,31,33 and indirect financial demands
of a cancer diagnosis.32
Limitations and Future Research
These data and conclusions must be considered within the
limitations of the study, which was a secondary analysis of
larger studyof patient-oncologist communication thatwasnot
specifically focused on cost discussions. All the patients were
African American and more than 90% were female, which
limits the generalizability of the findings. However, we believe
that information about cost discussions among this under-
studied population, which is especially vulnerable to financial
toxicity, is important. Future research should assess what
patients want to know about treatment cost before the in-
teraction, determine which questions were answered, and
assess the patient’s level of understanding of cost discussions
after the interaction. In addition, cost discussion outcomes
were solely based on the coders’ observations because cor-
roborative patient self-report data were unavailable. Finally,
patient insurance status may play a role in cost discussions,
but because of national-level insurance changes during data
collection (ie, the Patient Protection and Affordable Care
Act), insurance data that could bemeaningfullymapped onto
the cost outcomes could not be collected.
In conclusion, cost discussions occurred in fewer than one
half of cancer treatment clinical interactions with African
American patients; they often were patient initiated and fo-
cused mainly on taking time off from work. The discussions
were not focused on cost per ASCO’s Value Framework
definition. The findings highlight that African American
patients are not a homogenous group58,59 because patient age
and perceived amount of and satisfaction with social support
played a role in the presence and frequency of cost discussions.
Interventions to educate patients to ask questions about cost
and train providers to sensitively and appropriately initiate
cost discussions with all patients are critical steps toward
more-informed patients, more-informed treatment decisions,
and the potential for less financial toxicity.2,17,18,60
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